Payment overview · 2025
General Payments
$1,095.00
12 reported records · 6 companies
Healthcare provider profile · identity verified
Romeo E Rojas, MD
Allopathic & Osteopathic Physicians|Internal Medicine · MIAMI, FL · NPI 1730178690
Verified facts
What the public records show
CMS Open Payments records show Romeo E Rojas, MD received $1,095.00 in general payments during 2025 across 12 reported records.
Biosense Webster, Inc. accounted for 44.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 8 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Mounjaro.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Farxiga by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 73 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 73 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Trulicity by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Biosense Webster, Inc. | Unresolved — no canonical attribution shown | $484.56 | 44.2% | 4 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $241.52 | 22.1% | 2 | 2025 |
| Impulse Dynamics (USA) Inc. | Unresolved — no canonical attribution shown | $177.51 | 16.2% | 2 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $152.46 | 13.9% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $19.54 | 1.8% | 1 | 2025 |
| Insmed, Inc. | Unresolved — no canonical attribution shown | $19.41 | 1.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,095.00 | 12 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| CARTO 3 Normalized: carto 3 |
Device | Biosense Webster, Inc. | $484.56 | 4 | 2025 |
Source payment records
|
|||||
| Optimizer Normalized: optimizer |
Device | Impulse Dynamics (USA) Inc. | $177.51 | 2 | 2025 |
Source payment records
|
|||||
| OFEV Normalized: ofev |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $152.46 | 2 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $121.82 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $119.70 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $19.54 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $19.54 | 1 | 2025 |
Source payment records
|
|||||
| Arikayce Normalized: arikayce |
Drug | Insmed, Inc. | $19.41 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 19 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
73 | 15 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
73 | 15 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 244 | 72 |
| Losartan Potassium | Losartan Potassium | 202 | 51 |
| Metformin Hcl | Metformin Hcl | 195 | 43 |
| Gabapentin | Gabapentin | 150 | 39 |
| Eliquis | Apixaban | 135 | 40 |
| Amlodipine Besylate | Amlodipine Besylate | 126 | 33 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 116 | 44 |
| Famotidine | Famotidine | 103 | 39 |
| Levothyroxine Sodium | Levothyroxine Sodium | 94 | 28 |
| Metoprolol Tartrate | Metoprolol Tartrate | 94 | 29 |
| Hydrochlorothiazide | Hydrochlorothiazide | 93 | 23 |
| Furosemide | Furosemide | 89 | 34 |
| Pantoprazole Sodium | Pantoprazole Sodium | 78 | 32 |
| Lisinopril | Lisinopril | 77 | 22 |
| Jardiance | Empagliflozin | 73 | 15 |
| Trazodone Hcl | Trazodone Hcl | 65 | 15 |
| Fluticasone Propionate | Fluticasone Propionate | 61 | 26 |
| Metoprolol Succinate | Metoprolol Succinate | 60 | 23 |
| Temazepam | Temazepam | 60 | 12 |
| Montelukast Sodium | Montelukast Sodium | 54 | 14 |
| Tamsulosin Hcl | Tamsulosin Hcl | 53 | 23 |
| Simvastatin | Simvastatin | 52 | 20 |
| Ozempic | Semaglutide | 48 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 48 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 46 | suppressed |
| Nifedipine Er | Nifedipine | 43 | 11 |
| Omeprazole | Omeprazole | 43 | 16 |
| Carvedilol | Carvedilol | 41 | suppressed |
| Memantine Hcl | Memantine Hcl | 40 | 12 |
| Donepezil Hcl | Donepezil Hcl | 35 | 16 |
| Hydralazine Hcl | Hydralazine Hcl | 34 | 16 |
| Entresto | Sacubitril/Valsartan | 33 | suppressed |
| Mirtazapine | Mirtazapine | 33 | 11 |
| Allopurinol | Allopurinol | 31 | suppressed |
| Vascepa | Icosapent Ethyl | 31 | suppressed |
| Celecoxib | Celecoxib | 28 | 13 |
| Farxiga | Dapagliflozin Propanediol | 28 | suppressed |
| Potassium Chloride | Potassium Chloride | 28 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 27 | 11 |
| Glipizide | Glipizide | 26 | suppressed |
| Levofloxacin | Levofloxacin | 26 | 25 |
| Xarelto | Rivaroxaban | 26 | suppressed |
| Alprazolam | Alprazolam | 25 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 25 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 25 | suppressed |
| Humalog | Insulin Lispro | 24 | suppressed |
| Lactulose | Lactulose | 24 | 11 |
| Lorazepam | Lorazepam | 24 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 24 | suppressed |
| Glimepiride | Glimepiride | 23 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 22 | 21 |
| Amiodarone Hcl | Amiodarone Hcl | 21 | suppressed |
| Atenolol | Atenolol | 19 | suppressed |
| Ezetimibe | Ezetimibe | 19 | suppressed |
| Ibuprofen | Ibuprofen | 19 | 12 |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 19 | suppressed |
| Mounjaro | Tirzepatide | 19 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 18 | 12 |
| Insulin Lispro | Insulin Lispro | 18 | suppressed |
| Latanoprost | Latanoprost | 18 | suppressed |
| Nystatin | Nystatin | 18 | suppressed |
| Spironolactone | Spironolactone | 18 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 17 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 17 | 17 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 17 | suppressed |
| Folic Acid | Folic Acid | 16 | suppressed |
| Anastrozole | Anastrozole | 15 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 15 | suppressed |
| Finasteride | Finasteride | 15 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 15 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 15 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 14 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 13 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 13 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 12 | suppressed |
| Budesonide | Budesonide | 12 | suppressed |
| Bumetanide | Bumetanide | 12 | suppressed |
| Carvedilol Er | Carvedilol Phosphate | 12 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 12 | suppressed |
| Januvia | Sitagliptin Phosphate | 12 | suppressed |
| Livalo | Pitavastatin Calcium | 12 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 12 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 12 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 12 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 12 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 12 | suppressed |
| Trulicity | Dulaglutide | 12 | suppressed |
| Azithromycin | Azithromycin | 11 | suppressed |
| Clonazepam | Clonazepam | 11 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 11 | suppressed |
| Humalog Mix 75-25 | Insulin Lispro Protamin/Lispro | 11 | suppressed |
| Methylprednisolone | Methylprednisolone | 11 | 11 |
| Valsartan | Valsartan | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,095.00 · 12 records | Biosense Webster, Inc. | AIRSUPRA, Arikayce, BREZTRI, CARTO 3, MOUNJARO, OFEV, Optimizer, ZEPBOUND | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Mounjaro play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error